Tumor necrosis factor (TNFa), both by direct action and by trafficking cells of the immune system, is implicated in cardiopulmonary derangements and PMN-mediated microvascular injury associated with gram-negative sepsis. We examined the effects of pretreatment with a monoclonal antibody to TNFa on PMN function, hemodynamic derangements, and alveolar capillary membrane damage in a septic porcine model. Anti-TNFa profoundly improved hemodynamic consequences in this model. Reduction in PMN CD11 / 18 receptor expression, lung myeloperoxidase activity, and attenuation of peripheral neutropenia (all P < 0.05) indicate that pretreatment significantly reduced lung sequestration of PMNs seen in septic controls. In contrast, PMN oxygen radical (02-) generation was not significantly different from unprotected septic animals. Despite the presence of circulating PMNs primed for 0°-burst, alveolar capillary membrane damage, assessed by bronchoalveolar lavage protein content and arterial Po2 was markedly attenuated in the treatment group (P < 0.05). We conclude that antiTNFa suppresses systemic hemodynamic actions of TNFa. Further, it prevents upregulation of PMN adhesion receptors inhibiting PMN/endothelial cell interaction. This prevents formation of a "microenvironment," protected from circulating oxidant scavengers, into which sepsis-activated PMNs release their toxic products. Pretreatment with anti-TNFa monoclonal antibody thus affords global protection in porcine Gram-negative sepsis. (J. Clin. Invest. 1993. 91:1459-1468
Introduction
Gram-negative septicemia in hospitalized patients is invariably associated with high morbidity and mortality ( 1) . Case fatality rates of 20-60% reflect the frequent development ofacute lung injury (2) and multiple nonpulmonary organ failure (3) , and the lack of effective therapeutic agents needed to prevent the high frequency of patient deterioration in sepsis syndrome.
Many pathophysiological derangements associated with gram-negative sepsis result from the release of endotoxin (4, 5) , the LPS component of bacterial cell walls, into the circulation. One key role of LPS appears to be the initiation of a cascade of "communication proteins" elaborated and released by the reticuloendothelial system (5) . These proteins or cytokines play an important role in inflammation, both by direct action on cells at sites ofinfection and by trafficking other cells of the immune system, such as polymorphonuclear leukocytes (PMNs) (6) . Of the numerous cytokines now recognized, tumor necrosis factor-a (TNFa)' has emerged in recent years as a critical chemical mediator of sepsis syndrome (7) (8) (9) . TNFa is a 1 7-kD peptide produced predominantly by members ofthe mononuclear phagocyte system in response to particulate and soluble inflammatory stimuli (10) . Transcription of the gene for TNFa proceeds rapidly after exposure to inflammatory stimuli, with resultant extracellular release occurring within 15 min ( 11 ). The TNFa gene codes for a 233-amino acid protein, which undergoes proteolytic cleavage of a 76-residue signal peptide leaving a 157-amino acid active cytokine (12) . This secreted protein contains one intrachain disulfide bridge and exists as a dimer or trimer in circulation ( 13) .
Significant clinical and experimental evidence implicates TNFa as central to the pathogenesis of septic shock. Elevated TNFa plasma levels are detected with greater frequency in septic patients ( 14) and plasma levels of TNFa correlate in some series with severity of illness and mortality rates ( 15 ) . Several animal and human studies show prompt surges of TNFa in circulation after intravenous injection of LPS (16, 17) , with metabolic and pathophysiological consequences that mimic Gram-negative septicemia ( 18) . Animals (e.g., C3HEJ mice) resistent to the effects of endotoxin appear to have protection conferred by a genetic inability to manufacture native TNFa (19, 20) . These findings strongly suggest a pivotal role for TNFa in the evolution of septic shock from Gram-negative aerobic organisms.
A growing body ofevidence implicates blood PMNs as primary mediators ofend organ damage associated with multisystem organ failure in sepsis, particularly the alveolar capillary membrane damage characteristic of sepsis-associated acute lung injury (21, 22) . Using a porcine model of septic acute lung injury, our laboratory has previously correlated the appearance ofTNFa in the circulation with priming ofPMNs for toxic oxygen metabolite generation, increased expression of PMN /2 integrins, and consequent loss of PMNs from the circulation (23) . In vitro studies indicate that TNFa activates PMNs for oxidant generation, phagocytosis, degranulation, and adherence (24) (25) (26) . Although augmentation ofthese critical functions primarily prepares PMNs for first line immune defense, these functions are equally capable of precipitating host tissue damage.
In light of this evidence, we hypothesized that TNFa provides a link between bacteremia and PMN activation and that activated PMNs interact with the pulmonary endothelium, giving rise to alveolar capillary membrane damage by the action of toxic metabolites. To verify this we used an mAb directed at biologically active circulating TNFa. We sought to sever this TNFa link, thereby preventing PMN activation and thus attenuating the lung injury associated with the porcine model ofexperimental sepsis. In light ofsystemic TNFa effects (18), we also predicted a modification of the hemodynamic derangements characteristic of experimental Gram-negative septicemia (27) . Our studies readily demonstrate significant protection against lung injury and altered hemodynamic performance in this model. Of striking interest was the discovery of conflicting effects on PMN function, with near complete inhibition of CDl 1 / 18 adhesion receptor expression but persistence of enhanced oxygen radical generation. We suggest that inhibition of adhesion receptor expression prevents the interaction of the activated PMN with pulmonary capillary endothelium and therefore prevents toxic PMN metabolites from mediating alveolar capillary membrane injury. Further, by preventing both direct systemic actions ofTNFa and PMNendothelial interaction, mAb to TNFa also inhibits the evolution ofthe cardiopulmonary derangements typical ofthis experimental model. Methods mAb to TNFa. The IgGl antibody used for these studies was kindly provided by Miles Inc. (Berkeley, CA). The antibody was purified from murine hybridoma culture harvests via cell separation, polyethylene glycol precipitation, anion exchange, and size-exclusion chromatography. Purified antibody was 99% pure with fully functional binding to human TNFa. Endotoxin levels in all lots were < 2 pg/mg protein (Limulus assay). Stabilization was performed with glycine and maltose before lyophilization. Lyophilized mAb was stored at 4°C and reconstituted in sterile H20 immediately before infusion.
Animal preparation and conditioning. Yorkshire pigs were obtained from a commercial vendor and housed in the Virginia Commonwealth University vivarium for 3-5 d before study. All animals received benzethine and procaine penicillin G (300,000 U each) intramuscularly 48 h before study as a part of preoperative conditioning. The experimental protocol used for these studies was approved by the Institutional Animal Care and Use committee of Virginia Commonwealth University and adhered to National Institutes of Health guidelines for the use of experimental animals.
The porcine model. Young swine weighing 15-20 kg were preanesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and placed supine. Sodium pentobarbital ( 10 mg/kg) was then administered intravenously to induce anesthesia. Tracheostomy was performed and the trachea intubated with a cuffed endotracheal tube (Argyle, Tullamore, Ireland). Mechanical ventilation was commenced using a large animal ventilator (Harvard Apparatus, Boston, MA) using 0.5 FiO2 and 5 cm H20 positive-end expiratory pressure. The ventilator was set to deliver a tidal volume of 15 ml/kg with a respiratory frequency adjusted in all animals to produce a PaCO2 of 40 torr at the beginning ofeach experiment. Throughout the period ofstudy, anesthesia was maintained by continuous-infusion pentobarbital (5 mg. kg-' -h-'). Indwelling catheters were placed in the left common carotid artery for systemic arterial pressure monitoring and arterial blood gas determination as well as the left external jugular vein for infusion of saline, Pseudomonas organisms, and mAb. An indwelling balloon-tipped pulmonary arterial catheter was inserted via the right external jugular vein and positioned in the pulmonary artery via pressure monitoring for measurement of pulmonary arterial pressure, pulmonary arterial occlusion pressure, central venous pressure, and thermodilution cardiac output (28) (COMI; American Edwards, Santa Ana, CA).
Bronchoalveolar lavage (BAL). BAL was performed through the indwelling endotracheal tube using a fiberoptic bronchoscope (Model BF 4; Olympus Corp., New Hyde Park, NY) at 0 and 300 min in the right and left lungs, respectively. The distal end of the bronchoscope was gently wedged into third-or fourth-order bronchi of the middle and lower lobes. Each lobe was lavaged with two aliquots of 25 ml sterile saline. BAL fluid was centrifuged at 400 g and 40C for 10 min, and the supernatant was stored at 40C. Cell pellets were resuspended in Dulbecco's PBS containing 0.01% BSA. Cell counts were determined using a hemacytometer, and slide-directed cytocentrifugation was performed (Shandon Southern Instruments, Inc., Sewickley, PA). Differential counts were performed on 200 cells stained using a modified Wright-Giemsa (Diff-Quik"; Baxter Scientific, McGaw Park, IL). BAL protein was measured in the noncellular fraction by the bicinchoninic acid method (29) .
Total white blood cell counts. Arterial blood samples were drawn into sterile glass tubes containing 0. 15% EDTA and kept at 4VC (Vacutainer). Small aliquots of blood were set aside for white blood cell counts and blood smear differentials, which were performed as described above. The remainder was centrifuged at 500 g and 40C for 20 min and the resulting plasma was stored at -20'C.
PMN isolation. At 0 and 300 min arterial blood samples were drawn into sterile syringes containing 0.15% EDTA. PMNs were immediately isolated by dextran sedimentation and Ficoll-Hypaque density gradient centrifugation as described previously (30) . Cells counts and viability were confirmed using hemacytometer and trypan blue exclusion, respectively.
TNF assay. The L929 murine fibroblast bioassay was used to measure plasma TNFa levels (31 ) . L929 cells were seeded into 96-well flat-bottomed microtiter plates (Costar Corp., Cambridge, MA) at a density of 4 x 104 cells per well in 100 ,d DME with 5% FCS (DME-FCS; GIBCO/Bethesda Research Laboratories, Gaithersburg, MD) and incubated overnight at 37°C in a 5% CO2, 95% air atmosphere.
Spent medium was removed and replaced with 100 ul of DME-FCS containing 2 ,ug/ml actinomycin D (Merck Sharp & Dohme, West Point, PA). 100 td of serial log2 dilutions of test samples was added in duplicate. Recombinant human TNFa (Cetus Corporation, Emeryville, CA) was used as a positive control. Plates were incubated 18 h (37°C, 5% CO2). Medium was decanted and the remaining viable cells were stained for 10 min with 0.5% crystal violet in 20% methanol, rinsed in water, and air dried. Absorbance at 550 nm was determined using a microplate reader (Model EL309; Bio-Tek Instruments, Inc., Burlington, VT) blanked to noncellular reagent wells ( 100% cytotoxicity). Infinite dilutions of rTNFa were considered 100% survival. The percent cytotoxicity was calculated using the formula % cytotoxicity = 1 -(ODsample/IDcontrol). Units ofTNFa were defined as the reciprocal of the dilution resulting in 50% cytotoxicity.
Immunophenotyping. Direct immunophenotyping was performed using a mAb (60.3; Oncogen, Seattle, WA) that recognizes a functional epitope on the CD 18 adhesion receptor, and an isotypic IgG2a control (Mouse IgG2a, UPC 10; Sigma Chemical Co., St. Louis, MO). Both antibodies were previously conjugated with FITC (32). Arterial blood samples from study animals were drawn into polypropylene tubes containing 0.15% EDTA and 0.1% NaN3 and immediately placed on ice. I00-z1 aliquots of blood were then incubated with an equal volume of mAb 60.3 or IgG2a control for 20 min at 4°C such that the final concentrations were at antibody excess (previously established by antibody titration curves). Samples were washed twice with PBS containing 0.1% EDTA, 0.1% NaN3, and 0.2% BSA at 40C. Erythrocytes were lysed with NH4C1 buffer and cells were resuspended in PBS. Cells were shielded from light at 4VC before analysis. Analysis was performed on a flow cytometer with a four-decade, 1,024-channel, logarithmic amplifier (FACScanO Becton Dickinson & Co., Mountain View, CA). PMNs were gated according to forward angle and 900 light scatter characteristics. A minimum of 5,000 events were analyzed for each sample, and the mean channel fluorescence of gated PMNs was calculated. Mean channel fluorescence, a logarithmic function, was converted to a linear scale using fluorescent microbead standards and Quickcal software (Flow Cytometry Standards Corp., Research Triangle Park, NC). Fluorescence due to the nonspecific IgG2a antibody was subtracted from mAb 60.3 fluorescence to yield specific binding that directly reflects the expression of CDl 1 / 18. Results are expressed as molecules of equivalent soluble fluorochrome.
Superoxide anion assay. Superoxide anion production was determined by measuring the SOD inhibitable reduction of cytochrome c using a dual-beam spectrophotometer (Shidmadzu Scientific Instruments Inc., Columbia, MD). PMNs ( 106/ml) and cytochrome c ( 100 ,gM) were combined in a thermostat-controlled stirred cuvette (370C).
An identically prepared reference cell contained reaction products plus SOD (300 U/ml). The reaction was started by adding phorbol myristate acetate (PMA) (200 ng/ml) to each cuvette. The change in absorbance at 550 nm was continuously recorded for 10 min. Results are expressed as the rate of°2 production (nmol * min-' * 10-6 PMN) based on an extinction coefficient of: Ac550 = 2.10 X 104 M/cm.
Hypochlorous acid HOC/ production. Generation ofthe long-lived PMN oxidant, HOCI, was measured in freshly isolated blood PMNs by the taurine-trapping method (33) . Briefly, quintuplicate 100-,d aliquots of freshly isolated PMN (4 X 106/ml PBS) were added to the wells of a flat-bottomed microplate (Costar Corp.). 100 Ml of PBS containing 30 mM taurine, 1.5 mM previously reduced 5-5'-dithio-bis-2-nitrobenzoic acid, and 400 ng/ml PMA was added to initiate the reaction. The decrease in absorbance at 410 nm was recorded (vs. noncellular reagent blanks) in a microplate reader (Bio-Tek Instruments, Inc.) over 30 min. The concentration of TNB was determined using the extinction coefficient: AE410. = 1.36 X 104 M/cm. Lung myeloperoxidase content. At 300 min animals were killed by infusion of pentobarbital ( 100 mg/kg) and the right lung was excised immediately. Multiple random samples from all lobes were obtained, weighed, and homogenized (s-45 homogenizer; Virtis Co. Inc., Gardiner, NY) in 4 ml of 20 mM potassium phosphate buffer (pH 7.4). The homogenate was then centrifuged (40,000 g, 4°C, 30 min; L5-65 Ultracentrifuge; Beckman Instruments, Inc., Fullerton, CA). The pelleted material was resuspended in 4 ml 50 mM potassium phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl ammonium bromide (HTAB) (Sigma Chemical Co.) and frozen at -70°C. Before assay batched samples were thawed, sonicated for 90 s, incubated for 2 h (60°C), and centrifuged (1,000 g, 30 min, 4C Experimental design. Three groups ofanimals were studied. Group I (control, n = 10) received a 60-min intravenous infusion of sterile saline. Group II (sepsis, n = 10) received a 60-min intravenous infusion of live Pseudomonas aeruginosa, PAO strain (5 X 0 10 CFU/ml at 0.3 ml.20 kg-'min-'). Group III (anti-TNFa, n = 8) were pretreated with mAb to TNFa (5 mg/kg i.v.) 15 
Results

Plasma TNF activity
Plasma TNFa levels surged in group II (sepsis) animals within 60 min, reaching a peak of 4.54±0.47 U/ml at 120 min, and remained significantly elevated over baseline and control values at 300 min. Group I (control) and group III (anti-TNFa) animals showed no significant increase in plasma TNFa activity throughout the study period (Fig. 1) .
Physiology ofporcine sepsis and effects ofanti-TNFa antibody Group II (sepsis) animals exhibited significant cardiopulmonary derangements after onset of sepsis (Table I ). These derangements included early-phase pulmonary arterial hypertension and rapidly developing systemic arterial hypotension associated with significant deterioration of cardiac output. In the latter phases of sepsis, group II (sepsis) animals failed to recover cardiac function and exhibited sustained pulmonary arterial hypertension and systemic arterial hypotension, which was associated with an evolving metabolic acidosis and the development ofsignificant arterial hypoxemia over the period ofobservation (Fig. 2) . In contrast, group III (anti-TNFa) animals showed significant improvement in many cardiopulmonary derangements after the onset of Pseudomonas sepsis. After an initial decline in cardiac output during the 60-min Pseudomonas infusion, group III (anti-TNFa) animals exhibited rapid recovery to baseline levels ( Table I ). The progressive systemic arterial hypotension and metabolic acidosis observed in group II (sepsis) animals were not observed in group III animals (anti-TNFa). Further, anti-TNFa treatment abolished the development of significant systemic arterial hypoxemia (Fig. 2) . However anti-TNFa failed to improve the early septic pulmonary arterial hypertension. 137±15 ,g/ml, P < 0.05). Although group III (anti-TNFa)
animals also showed an increase in BAL protein content at 300 min (313±48 vs. 141±19 ,ug/ml), this was significantly less than that observed in group II (sepsis) (P < 0.05) (Fig. 3) .
Neutrophil trafficking
Peripheral white cell counts. Group II (sepsis) animals became significantly neutropenic within 30 min, reaching a nadir at 120-180 min (Fig. 4) Time (h) Figure 5 . Circulating PMN morphology was monitored by examining cytocentrifuge preparations in animals from all groups during the 300-min period. Although total WBC counts differed significantly between group II (sepsis) and group III (antiTNFa) animals at 300 min (Fig. 4) , the maturity of the PMN forms found in circulation did not. Equal numbers of immature PMNs (i.e., band forms, myelocytes) were observed between septic and antibody-treated animals (data not shown).
Neutrophil CDJ /CD18 expression. PMNs obtained from group II (sepsis) animals exhibited significant upregulation of CD 1 / 18 expression compared with baseline and control values (Fig. 5) . Peak values were observed from 120 to 240 min. In contrast, PMNs from group I (control) and group III (antiTNFa) animals showed no significant upregulation of CDl 1 / 18 expression over the course of study (Fig. 5) .
Lung neutrophil load. Myeloperoxidase content oflung tissue from animals in each study group was analyzed to assess lung PMN burden (Fig. 6 ). Group II (sepsis) animals exhibited significantly higher myeloperoxidase content in lung tissue when compared with group I (control) animals (51.6±9.9 vs.
11.3±2.8 U/g, P < 0.001). In group III (anti-TNFa) animals, pretreatment with anti-TNFa antibody greatly reduced lung PMN burden when compared with group II (sepsis) animals (25.4±3.3 vs. 51.6±9.9 U/g, P < 0.05). Thus, antibody treatment reduced lung PMN content despite an ongoing septic process.
Neutrophil transendothelial migration. PMN counts in recovered BAL lavage fluid, expressed as a percentage ofthe total recovered white cell count, were not significantly different between groups at time 0 (Fig. 7) . In group II (sepsis) lavage recovered significantly (P < 0.05) more PMNs at 300 min (24.5±6.7, P < 0.05) than at 0 min (1.8±0.4) and group I (control) at 300 min (3.9±1.4). There was no significant increase in PMNs recovered from BAL at time 300 (13.6±6.5) compared with time 0 (4.7±1.4) in group III (anti-TNFa) animals.
Neutrophil oxidant production. PMNs obtained from group II (sepsis) animals at 300 min demonstrated a marked priming response for PMA-stimulated O2 production when compared with baseline PMNs, as noted by an increase in both rate of production and peak production of O2 (Fig. 8) . In contrast, PMNs from group I (control) animals showed no priming over the course of study. Pretreatment with antiTNFa antibody failed to attenuate enhanced PMN short-lived oxidant generation. We found that PMNs obtained at 300 min from group III (anti-TNFa) animals showed a similar degree of priming as that observed in group II (sepsis) animals. To determine whether the lack ofPMN CD 18 upregulation in antibody-treated septic animals was a mAb 60.3 epitopespecific phenomenon, an additional CD18 mAb (IB4) that crossreacts with porcine PMNs was used (34) . We found that IB4 fluorescence patterns on PMNs from both septic and septic anti-TNFa-treated animals were identical to fluorescence patterns presented for mAb 60.3 (Fig. 5) , suggesting that the results are not epitope specific.
Finally, we examined whether failed upregulation of PMN CD 18 was a permanent cell surface defect, perhaps resulting from interference by anti-TNFa/TNFa complexes or antiTNFa nonspecific Fc interactions with PMNs. In this study, PMNs were isolated as described above in four animals at baseline (before antibody and Pseudomonas infusion) and at 5 h after antibody and organism infusion. Isolated PMNs were incubated with rTNFa ( 1,000 U/ml) or PMA (200 ng/ml) for 30 min at 370C. CD18 expression was then measured using mAb 60.3. PMNs from antibody-treated animals isolated after 1464 Windsor et al. a 5-h septic insult remained capable of significantly upregulating CD 18 receptors when exposed to both rTNFa and PMA (229±8 and 338±25% of control fluorescence, respectively, at baseline; 168±12 and 315±56%, respectively, at 5 h, P < 0.05). Thus, failed upregulation of CD1 8 observed in vivo was not a "permanent" PMN defect. PMN from antibody-treated septic animals obtained at 5 h upregulated CD1 8 significantly less after rTNFa exposure than did rTNFa-stimulated baseline PMN (168±12 vs. 229±8%, P < 0.05). These findings may result from nonspecific Fc binding of anti-TNFa antibody to PMN, subsequently reducing rTNFa activity in vitro. In all cases, however, rTNFa and PMA produced CD 18 fluorescence that was significantly greater than control unstimulated PMN.
Discussion
In this as in other studies, the key humoral response to unprotected sepsis is the early phasic surge of TNFa in the circulation. Abolition of this TNFa response by passive immunization with a mAb to TNFa profoundly alters the evolution of both the hemodynamic and alveolar capillary membrane derangements associated with this model ofGram-negative septicemia. Ofparticular interest is the finding that isolation and inhibition ofonly one of many humoral components ofthe complex chemical network associated with sepsis affords such global protection. With respect to hemodynamic effects, we observed maximal protection at 60 min of sepsis and beyond. This is in keeping with previously reported hemodynamic protection afforded by a higher dose of anti-TNFa (15 mg/kg) (35) . In both ofthese studies, early-phase pulmonary arterial hypertension and decrements in cardiac index persist, despite antiTNFa antibody pretreatment. An early fall in arterial oxygen tension (PaO2) and an arterial acidosis was observed in antibody-treated animals, however, both variables recovered to near baseline levels beyond 60 min. These findings suggest that early changes in cardiopulmonary variables are mediated by other humoral components of sepsis, (e.g., thromboxane), an observation confirmed by previous reports using cyclooxygenase inhibition (36) and the detection ofhigh thromboxane levels at 30 min in animals treated with high dose (15 mg/kg) anti-TNFa (35) .
Significant evidence has accumulated from in vitro and in vivo studies that suggests that PMNs play a significant role in many inflammatory states. Of particular importance is evidence that suggests that PMNs are primary cellular mediators of acute lung injury associated with sepsis. Histological examination of postmortem lungs of PMN-sufficient patients who died from acute respiratory distress syndrome (ARDS) invariably shows large numbers of sequestered PMNs in pulmonary microvasculature (37) (38) (39) (40) . Further evidence is provided by studies that show large numbers ofPMNs recovered from BAL fluid of patients suffering from ARDS (41, 42) . High levels of PMN elastase-al protease inhibitor complexes are found in the same lavage fluids, suggesting that PMNs rapidly migrated from the vascular space and were actively degranulating (43) (44) (45) . Weiland and others correlated the appearance ofPMNs in the lavage fluid of ARDS patients with clinically deteriorating oxygenation (42) and with the development ofan acute peripheral neutropenia reported in numerous animal models of sepsis-induced acute lung injury (46) (47) (48) . Preinjury depletion of circulating PMNs in these models attenuates the resulting lung injury (49) (50) (51) (52) (53) . More recently, functional manipulation ofthe PMN has provided striking evidence of the importance of PMNs to the development oflung injury. Inhibiting PMN oxygen radical generation using cyclooxygenase inhibitors (e.g., ibuprofen) leads to significant attenuation of lung injury in animal models when used in pre-or postinjury treatment protocols (36, 54 Transient early-phase peripheral neutropenia (Fig. 4) is a phenomenon noted in previous reports from our laboratory (56) . Recent (59) . This binding provides strong adhesive forces necessary for migration of PMNs across vascular endothelium (59) . Coincident with PMN activation and upregulation of CD 1 / 18 receptors, there is equally rapid shedding of PMN L-selectin receptors, resulting in release of the initial arresting receptor complexes. Early loss of PMNs from the circulation in our studies is unlikely to be due to L-selectin/ ELAM-l binding, since ELAM-1 expression is dependent upon protein synthesis and is maximal at 4 h. However, GMP-140 stored in cytosolic Wiebel-Palade granules within endothelial cells can be mobilized to the cell surface within minutes of cellular activation and is therefore upregulated within the time frame of this neutropenia (65) . We speculate that early-phase peripheral neutropenia observed in our studies results from L-selectin/GMP-140 interaction, which produces temporary lung sequestration. PMNs removed from circulation in this fashion but prevented from upregulating CDl (68) . Prevention of these membrane events by blocking circulating TNFa activity in sepsis may inhibit vital steps required for emergence of preformed intracellular receptor glycoproteins necessary for PMN adhesion. The possibility that this finding in our model resulted in permanent inhibition of receptor expression was also investigated. Results indicated that the PMN obtained from antibody-treated septic animals retained the ability to upregulate their CD1 8 receptors in the absence of anti-TNFa antibody.
Numerous reports point to a role for TNFa in both priming PMNs for oxidant burst activity in response to secondary stimuli and for inducing generation and release of reactive oxygen species (69, 70) . Korchak and Weissman (71 ) reported that receptor-ligand interaction results in measurable changes in target cell membrane electropotentials before activation of the membrane-associated NADPH oxidase enzyme system. Seeds et al. (72) later postulated that changes in membrane potentials could regulate potential-dependent conformational changes of membrane proteins (i.e., "electromorphostasis") and thus control early membrane-associated cellular functions. One might therefore predict that a proposed anti-TNFa-mediated, alteration in membrane configuration responsible for inhibiting CD 1 / 18 receptor expression would also affect oxidant metabolism. This was not the case in our studies. Generation of both short-and long-lived oxidant species in the treatment group was not different from that observed in unprotected sepsis. Nathan (73) Thus, we have demonstrated that isolation ofa single chemical mediator, TNFa, leads to paradoxical effects on PMN function in this model of experimental sepsis. It seems likely that the persistence of enhanced oxidant generation by PMNs obtained from anti-TNFa-treated animals results from the presence in circulation of humoral mediators other than TNFa. Endotoxin, eicosanoids, and complement degradation products prime PMNs for enhanced oxidant burst (76) . The continued presence of these and other proinflammatory mediators in the circulation of these animals thus activate the PMN in TNFa-deficient sepsis. Despite the presence of other humoral mediators, we observed no upregulation of CD 11/18 receptors in the anti-TNFa-treated animals. These results contrast sharply with in vitro studies that suggest mediators such as complement degradation products and LPS are capable of upregulating CD1 1 / 18 receptors in the absence ofTNFa (57) . These findings further suggest that, in this model, biologically active TNFa is required by the PMN to promote surface expression of 02 integrins during sepsis (vide supra).
Finally, our results show excellent protection against alveolar capillary membrane injury with preserved gas exchange. BAL protein concentration, an indicator of protein leak from the pulmonary microvasculature, was significantly reduced when compared with unprotected animals at 300 min. Despite the early drop in arterial oxygenation, we observed complete recovery to approximately control levels beyond 60 min. This observed protection is likely due in part to blocking the direct effects of TNFa on endothelial surfaces. It is of further interest that, although the PMNs remain capable of oxygen radical generation, they fail to mediate significant endothelial injury typical of septic-unprotected animals. This protection would appear to support the "microenvironment theory" (77) of PMNmediated tissue injury. This theory suggests that adherence of activated PMNs to endothelium creates an intercellular microenvironment into which PMNs secrete toxic products such as reactive oxygen metabolites and proteinases and that this microenvironment is protected from the action of circulating oxidant scavengers and proteinase inhibitors permitting unchecked endothelial injury. Our work suggests that preventing upregulation of CD 1 / 18 receptors after onset of sepsis inhibits PMN adhesion and thus prevents the formation of sufficient microenvironmental surface area in the pulmonary microvasculature to produce the extent of endothelial damage observed in unprotected animals. The postulate that there is reduced PMN adhesion and hence sequestration in lung microvasculature is supported by the observed reduction in lung myeloperoxidase activity in the antibody-treated compared with untreated septic animals.
In conclusion, the application of a mAb against TNFa in experimental sepsis confers both hemodynamic and alveolar capillary membrane protection. Further, antibody treatment alters PMN kinetics as a result of inhibiting CD 1 / 18 receptor expression but has no effect on PMN oxygen radical generation. This study has isolated critical mechanisms through which TNFa acts in an in vivo situation, complicated by the complex network of other chemical and cellular components of the septic response. Such global protection in this pretreatment model begs further examination of this antibody in posttreatment protocols and future clinical trials.
